Switch to: Citations

Add references

You must login to add references.
  1. The Economics of Climate Change.Nicholas Stern - 2007 - Environmental Values 16 (4):532-536.
    Download  
     
    Export citation  
     
    Bookmark   188 citations  
  • (1 other version)What Will It Take to Address the Global Threat of Antibiotic Resistance?Steven J. Hoffman & Kevin Outterson - 2015 - Journal of Law, Medicine and Ethics 43 (2):363-368.
    In March 2015, the Dag Hammarskjöld Foundation convened a workshop in Uppsala, Sweden to address questions about antibiotic resistance, in partnership with the Global Strategy Lab, the Journal of Law, Medicine & Ethics, the Norwegian Institute of Public Health, and ReAct – Action on Antibiotic Resistance. Eleven concise articles were commissioned to explore whether ABR depended on global collective action, and if so, what tools could help states and non-state actors to achieve it. This article introduces that collection, which is (...)
    Download  
     
    Export citation  
     
    Bookmark   9 citations  
  • The Tragedy of the Commons.Garrett Hardin - 1968 - Science 162 (3859):1243-1248.
    At the end of a thoughtful article on the future of nuclear war, Wiesner and York concluded that: "Both sides in the arms race are... confronted by the dilemma of steadily increasing military power and steadily decreasing national security. It is our considered professional judgment that this dilemma has no technical solution. If the great powers continue to look for solutions in the area of science and technology only, the result will be to worsen the situation.".
    Download  
     
    Export citation  
     
    Bookmark   920 citations  
  • The Pharmaceutical Commons: Sharing and Exclusion in Global Health Drug Development.Catherine M. Montgomery & Javier Lezaun - 2015 - Science, Technology, and Human Values 40 (1):3-29.
    In the last decade, the organization of pharmaceutical research on neglected tropical diseases has undergone transformative change. In a context of perceived “market failure,” the development of new medicines is increasingly handled by public-private partnerships. This shift toward hybrid organizational models depends on a particular form of exchange: the sharing of proprietary assets in general and of intellectual property rights in particular. This article explores the paradoxical role of private property in this new configuration of global health research and development. (...)
    Download  
     
    Export citation  
     
    Bookmark   12 citations